The HTA Philippines, in collaboration with the WHO, is now calling for proposals for the health technology assessment of 2022 priority mental health drugs for inclusion in the Philippine National Formulary. Call for submissions will run from October 2 – 14, 2024 For more details, and submission instructions, please access link below: https://www.ungm.org/Public/Notice/248461
[FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients
Published on 01 October 2024 As of 23 September 2024, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients for possible inclusion in the Philippine National Formulary (PNF). As such, the HTA Council hereby makes continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) Patients
STATUS UPDATES ON THE HTA NOMINATIONS FOR CYCLE 3 TOPICS
We would like to inform our stakeholders that the HTA Council will accept nominations only from the Department of Health (DOH) and Philippine Health Insurance Corporation (PhilHealth) in 2024, and open the Call for Nominations to other stakeholders in the 4th quarter of 2025 for Cycle 3 Topics based on the status of ongoing assessments. continue reading : STATUS UPDATES ON THE HTA NOMINATIONS FOR CYCLE 3 TOPICS
[FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke
Published 25 September 2024 As of 20 September 2024, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Citicoline for Ischemic Stroke Patients for possible inclusion in the Philippine National Formulary (PNF). As such, the HTA Council hereby makes public its preliminary recommendation on the non-inclusion in the PNF continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke
[FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Pneumococcal Conjugate Vaccines (PCV) for infants less than 1 year old and children aged 13 to 23 months for catch-up immunization
Published 25 September 2024 As of 20 September 2024, the Health Technology Assessment Council (HTA Council) has completed the evidence appraisal on the assessment of Pneumococcal Conjugate Vaccines (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization. The HTA Council assessed the following PCV products for continue reading : [FOR PUBLIC CONSULTATION] HTA Council Preliminary Recommendation on Pneumococcal Conjugate Vaccines (PCV) for infants less than 1 year old and children aged 13 to 23 months for catch-up immunization